Alembic has rallied 12% in the last two days and has touched a high of Rs.874. The stock price has doubled from its recent low of Rs.436 on March 23, 2020. Alembic’s total revenues grew 30% to Rs.1207. EBITDA margins expanded by 900 basis points to 28%. Also, Alembic is entering the last leg of its capex plan, which is likely to be a medium term building block for the company. The domestic business is also back to double-digit growth after nearly six quarters of tepid performance. In addition, Alembic’s associate company (Rhizen Pharma) is expected to start contributing meaningfully in FY21 with its first out-licensed product.